TiumBio will present updated interim phase 2 data for TU2218 (tosposertib) in combination with Keytruda (pembrolizumab) in recurrent or metastatic head and neck cancer.

tosposertib (NCE 401) - Tium Bio, Chiesi

May 25, 2026